Citi Remains Bullish on Veradermics, Incorporated (MANE)

Veradermics, Incorporated (NYSE:MANE) is one of the best performing healthcare stocks so far in 2026. On April 27, Citi lifted the price target on Veradermics, Incorporated (NYSE:MANE) to $120 from $85, reaffirming a Buy rating on the shares. The rating update came after the company announced positive topline results from Part A of its Phase 2/3 trial evaluating VDPHL01 in male pattern hair loss. The firm stated that the data “exceeded our base-case bar across all endpoints”, adding that the safety profile was clean. Citi lifted its view of the odds of success to 75%, and now models 2035 risk-adjusted peak sales of $3 billion, up from the previous $2 billion.

Veradermics, Incorporated (NYSE:MANE) announced on April 27 positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating VDPHL01 in over 500 males with mild-to-moderate pattern hair loss. VDPHL01 is a proprietary extended-release oral minoxidil formulation, and Veradermics, Incorporated (NYSE:MANE) believes that the result positions the formulation to potentially become the first FDA-approved oral pill for pattern hair loss in nearly 30 years, as well as a potential best-in-indication treatment option for the 50 million men with pattern hair loss in the United States.

Veradermics, Incorporated (NYSE:MANE) is a late clinical-stage biopharmaceutical company with a focus on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent dermatological and aesthetic conditions.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.